What does Hirundo Biosciences do?
B.C.I. Pharma specializes in the development and commercialization of innovative pharmaceutical products. The company focuses on providing solutions for various therapeutic areas, aiming to improve patient outcomes. With a commitment to quality and research, B.C.I. Pharma is dedicated to advancing healthcare.
- Sectors
- Real estate agencies
- Activities
- Signals
-
Reporting lossesReporting losses € -1.26M
The company reported a loss in the latest financial year.
Poor liquidityPoor liquidity 0.11The current ratio is below 1: may be insufficient to cover short-term debt.
Negative cashflowNegative cashflow € -90KOperating cash flow was negative in the latest financial year.
Negative EBITDANegative EBITDA € -86KEBITDA is negative: operating activities are loss-making.
Strong equityStrong equity € 1.79MStrong equity provides a buffer against setbacks.
Healthy social debtHealthy social debt 23.5%Social debts stay manageable relative to personnel costs.
Financial ratios
|
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
€
147K
|
€
644K
|
€
290K
|
€
936K
|
|
|
€
-86K
|
€
499K
|
€
141K
|
€
733K
|
|
|
€
-1.26M
|
€
-347K
|
€
-1.05M
|
€
-211K
|
|
|
€
1.79M
|
€
3.05M
|
€
3.40M
|
€
4.45M
|
|
|
25.98%
|
52.16%
|
57.99%
|
74.68%
|
|
|
€
5.10M
|
€
2.80M
|
€
2.46M
|
€
1.51M
|
|
|
|
€
74K
|
€
221K
|
€
336K
|
|
|
3.00
|
1.90
|
2.00
|
3.00
|
Publications 12
All publications- Rubrique Fin (Cessation, Annulation Cessation, Nullite, Conc, Reorganisation Judiciaire, Etc...) 05/02/2024
- Rubrique Fin (Cessation, Annulation Cessation, Nullite, Conc, Reorganisation Judiciaire, Etc...) 10/01/2024
- Rubrique Fin (Cessation, Annulation Cessation, Nullite, Conc, Reorganisation Judiciaire, Etc...) 23/10/2023
- Demissions, Nominations 20/09/2023
- Rubrique Fin (Cessation, Annulation Cessation, Nullite, Conc, Reorganisation Judiciaire, Etc...) 11/07/2023
Frequently asked questions
Answers to the most common questions about Hirundo Biosciences, based on official government data and the filed annual accounts.
What is the VAT number of Hirundo Biosciences?
The VAT number of Hirundo Biosciences is BE0681.855.065.
How many employees work at Hirundo Biosciences?
In 2024, Hirundo Biosciences employed 3.00 full-time equivalents (FTE).
When was Hirundo Biosciences established?
Hirundo Biosciences was founded in 28-09-2017.
What is the official address of Hirundo Biosciences?
The official address of Hirundo Biosciences is Boulevard De Patience Et Beaujonc 3 Liège 4000.
What is the legal form of Hirundo Biosciences?
The juridical form of Hirundo Biosciences is Public limited company (NV/SA).
What is the annual revenue of Hirundo Biosciences?
The 2024 accounts of Hirundo Biosciences do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.
What does Hirundo Biosciences do?
B.C.I. Pharma specializes in the development and commercialization of innovative pharmaceutical products. The company focuses on providing solutions for various therapeutic areas, aiming to improve patient outcomes. With a commitment to quality and research, B.C.I. Pharma is dedicated to advancing healthcare.
Is Hirundo Biosciences a reliable company?
Hirundo Biosciences is a registered Rechtspersoon with company number 0681.855.065 and can be verified through the official CBE database.
What is the credit limit of Hirundo Biosciences?
The estimated credit limit of Hirundo Biosciences is €63,158.
Is Hirundo Biosciences still active?
Hirundo Biosciences currently has the status "Normal situation" and is active.